Introduction {#Sec1}
============

Dermatophytosis are caused by fungi known as dermatophytes. These fungi have a strong biotropism by keratinized tissues, such as skin, hair, and nails. Thus, their ability to cause mycosis is dependent on keratin \[[@CR1]--[@CR3]\]. The incidence of dermatophytosis has increased over recent years, with a prevalence of 25% of the worldwide population \[[@CR4]--[@CR6]\]. Currently, they are considered the fourth most prevalent fungal infections worldwide \[[@CR7]\]^.^

*Candida* spp. yeasts are principal opportunistic fungal pathogens in humans and animals*. Candida* infections present worldwide occurrence and range from superficial and cutaneous candidiasis to more severe forms, such as invasive candidiasis and candidemias \[[@CR8], [@CR9]\]. The incidences of these infections have increased considerably in the last years \[[@CR10], [@CR11]\]. This fact is associated to the increase of the number of immunosuppressive individuals due to the HIV epidemic, chronic disease, or chemotherapies \[[@CR12], [@CR13]\].

The main problem involving fungal infection is the expansion of multidrug resistance \[[@CR14]--[@CR16]\]. This phenomenon is a global health problem and has led to failures in the clinical treatment and recurrence of infection, leading to increase cases of mortality \[[@CR2], [@CR17]\]. In addition, antifungals currently present high rates of toxicity to the patient, at the topical or systemic levels \[[@CR18]--[@CR21]\]. From this context, new strategies to combat antifungal resistance, such as the prospection of new compounds that can overcome the limitations of currently available antifungal agents, become essential.

Quinoline nucleus plays a fundamental role in the prospection of new therapeutic compounds with broad spectrum biological action \[[@CR22], [@CR23]\]. Some drugs containing the quinoline structural nucleus are commercially available, such as nitroxoline (antibacterial action), chloroquine and hydroxychloroquine (antimalarial action), and bedaquiline (multidrug-resistant tuberculosis action) \[[@CR24]--[@CR26]\]. At present, chloroquine and hydroxychloroquine have been considered a promising treatment in critical patients affected by coronavirus disease 2019 (COVID-19), current pandemic without specific therapeutic agents or vaccines and substantial mortality \[[@CR27], [@CR28]\]. Moreover, a variety of pharmacological proprieties of quinoline derivatives, such as anticancer, antimalarial, anti-inflammatory, antituberculosis, anti-*Toxoplasma,* antibacterial, and antifungal actions have been considerably related \[[@CR29]--[@CR38]\]. However, the antifungal actions of these derivatives against dermatophytic species are rare.

Considering that quinoline derivatives can be potentially active against different fungal species and present low toxicity, this study evaluated the antifungal effectiveness and toxicological parameters of quinolines derivatives against *Candida* and dermatophytes strains of difficult treatment.

Material and methods {#Sec2}
====================

Chemicals and reagents were purchased from commercial suppliers and used as directed by the manufacturer. The solvents were distilled under a nitrogen atmosphere when necessary. The reactions that required anhydrous conditions were carried out under a nitrogen or argon atmosphere. The reactions were monitored by thin layer chromatography (TLC) on 0.2 mm plates precoated with silica gel (Merck®) and visualized by spraying with different developers (sulfuric anisaldehyde, phosphomolybdic acid, and potassium permanganate) under heating, in addition under UV light. Evaporation and concentration of the solvents were done on the rotary evaporator using the vacuum pump. ^1^H NMR and ^13^C NMR spectra were measured on Bruker® 300 MHz equipment using SiMe~4~ (TMS) as an internal standard. Chemical shifts (^δ^) are given in ppm and the coupling constants (J) are given in Hertz. The deuterated solvent used was CDCl~3~. Splitting patterns were designated as follows: s = simplet, sl = singlet extended, d = doublet, dd = doublet doublet, ddd = doublet doublet, t = triplet, dt = doublet triplet, q = quartet, and m = multiplet. Purifications were performed by column chromatography using silica gel 60 (70--200 mesh and 40--60 mesh) or using silica gel 60 PF254 for preparative thin layer chromatography. Petroleum ether (PE) was used in the purifications with the fraction of low boiling point (40--60).
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Synthesis of 6-bromo 4-methylquinoline (1) {#Sec3}
------------------------------------------

In the reaction tube, 1 eq. (0.5 mMol, 86 mg) of 4-bromoaniline and 1 eq. (0.5 mMol, 116.15 mg) of camphorsulfonic acid (Bronsted acid) were added and dissolved in 2 ml of dichloroethane under stirring. Then, 2.4 eq. (1.2 mMol, 84, 10 mg, 100 μl) of the methyl vinyl ketone (MVK) were added. The reaction was performed under reflux in a 10 mL Pirex® brand sealed tube at inert atmosphere (N2) overnight. The reaction was monitored by thin layer chromatography (TLC). The solvent was evaporated under reduced pressure, and then dissolved in 20 mL of aqueous saturated sodium bicarbonate solution. The solution was extracted with diethyl ether (3 × 10 ml). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The quinoline was purified by column chromatography using petroleum ether and ethyl ether eluents in an increasing polarity 10:0 ➔ 9:1. Compound 1 was obtained as a brown solid in 42% yield. ^1^H NMR (300 MHz, CDCl~3~) δ ppm: H2 (8.78; d, J = 3.0 Hz, 1H), H5 (8.15; d, J = 2.2 Hz, 1H), H8 (7.97; d, J = 9.0 Hz, 1H), H7 (7.77; dd, J = 9.0 and 2.2 Hz, 1H), H3 (7.25; d, J = 3.0 Hz, 2H), and CH~3~ (2.68; s, 3H) as described previously by Ranu et al. \[[@CR39]\].

Synthesis of compounds 2, 3, 4, and 5 {#Sec4}
-------------------------------------

A solution of 2 ml of distilled dimethylformamide (DMF) and 1 eq. (0.5 mMol, 181.15 mg) of tert-butyl (2-iodophenyl) carbamate were added to a 10-mL Pirex® brand sealed tube under stirring at inert atmosphere (N2). Following 6 eq. (3 mMol, 246.09 mg) of the anhydrous sodium acetate (base), 1 eq. (0.5 mMol, 112.25 mg) of the Palladium (II) acetate and 2 eq. (1 mMol, 262.29 mg) of the triphenylphosphine were added. Then, 2.4 eq. (1.2 mMol) of the α,β-unsaturated ketone of interest were added (MVK for compound 2, (*E*)-3-hexen-2-one for 3, (*E*)-6-fenilhex-3-en-2-one for 4, and (*E*)-4-phenylbut-3-en-2-one for 5). The reaction was carried out overnight and monitored by thin layer chromatography (TLC) to observe the consumption of the reaction limiting reagent (aniline). Then, the solvent was evaporated under reduced pressure, and the crude reaction dissolved with 20 ml of saturated sodium bicarbonate solution. The crude reaction was extracted with diethyl ether (3 × 10 ml). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude reaction was transferred to a reaction flask and dissolved in 5 ml of distilled dichloromethane. Then, 10 eq. (5 mMol, 816.95 mg) of trichloroacetic acid were added at stirring for 4 h at room temperature. The solvent was evaporated under reduced pressure, and the residue was diluted in 20 ml of saturated sodium bicarbonate solution and extracted with diethyl ether (3 × 10 ml). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The product was purified by preparative plates with petroleum ether:ethyl ether in the ratio (9:1).

Compound 2-methylquinoline (2) was obtained as a brown solid in 70% yield. ^1^H NMR (300 MHz, CDCl~3~) δ ppm: H4 and H5 (8.02; t, J = 8.0 Hz, 2H), H8 (7.76; d, J = 8.5 Hz, 1H), H7 (7.66; ddd, J = 8.5; 7.0 and 1.4 Hz, 1H), H6 (7. -- 7.42; m, 1H), H3 (7.29; d, J = 8.1 Hz, 1H) and CH~3~ (2.75; s, 3H). ^13^C NMR (300 MHz, CDCl3) δ ppm: CH~3~ (25.4), C10 (126.5), C9 (147.9), C2 (158.9).
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Compound 2-methyl-4-ethylquinoline (3) was obtained as a brown solid in 77% yield. 1H NMR (300 MHz, CDCl3) δ ppm: H5 (7.99; dd, J = 7.6 and 1.8 Hz, 1H), H8 (7.85; dd, J = 7.7 and 1.9 Hz, 1H), H6 and H7 (7.54--7.45; m, 2H), CH~2~ (3.05; q, 2H), CH~3~ (2.66; s, 3H), and CH~3~′ (1.27; s, 3H). ^13^C NMR (300 MHz, CDCl~3~) δ ppm: C13 (CH~3~--13.6), C12 (CH~2~--18.2), C11 (CH~3~--20.4), C9 (142.6), C4 (145.6), and C2 (150.8).
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Compound 2-methyl-4-phenethylquinoline (4) was obtained as a brown solid in 37% yield. ^1^H NMR (300 MHz, CDCl~3~) δ ppm: H5 (8.06; dd, J = 8.4 and 0.6 Hz, 1H), H8 (8.00; dd, J = 8.4 and 1.0 Hz, 1H), H7 (7.70; ddd, J = 8.4 Hz; 7.00 and 1.4 Hz, 1H), H6 (7.48; ddd, J = 8.2; 7.00 and 1.4 Hz, 1H), phenyl (7.35--7.20; m, 5H), H3 (7.80: s, 1H), H1′ (3.33; dd, J = 9.6 and 6.6 Hz, 2H), H2′ (3.05; dd, J = 9.6 and 6.6 Hz, 2H), and CH~3~ (2.69; s, 3H). ^13^C NMR (300 MHz, CDCl~3~) δ ppm: C11 (CH~3~--25.2), C1' (CH~2~--34.1), C2′ (CH~2~--36.2), C1′′ (141.1), C9 (147.9), C4 (147.4), and C2 (158.7).
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Compound 2-methyl-4-phenylquinoline (5) was obtained as a brown solid in 17% yield. ^1^H NMR (300 MHz, CDCl~3~) δ ppm: H5 (8.08; d, J = 8.4 Hz; 1H), H8 (7.85; dd, J = 8.4 e 0.9 Hz, 1H), H7 (7.66; ddd, J = 8.4; 7.00 and 1.4 Hz 1H), phenyl and H6 (7.56--7.39; m, 6H), and H3 (7.24: s, 1H), CH~3~ (2.78; s, 3H). ^13^C NMR (300 MHz, CDCl~3~) δ ppm: C11 (CH~3~--25.3), C9 (138.1), C12 (148.4) C4 (148.5), and C2 (158.5).
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In silico ADME prediction {#Sec5}
-------------------------

The physicochemical parameters for the quinoline derivatives were calculated using the online tool SwissADME. In this platform, it is possible to have free access to a set of fast and robust predictive models for physico-chemical, pharmacokinetic, and pharmacological properties of synthesized compounds \[[@CR40], [@CR41]\], since the calculation of in silico ADME parameters through digital tools is a strategy used to accelerate the development process of new drugs. The percentage of oral absorption (% ABS) was calculated according to Zaheer et al. \[[@CR42]\] through of equation:$$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
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                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
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                \begin{document}$$ \%\mathrm{ABS}=109-\left(0.345\ \mathrm{x}\ \mathrm{PSA}\right) $$\end{document}$$

Fungal strains {#Sec6}
--------------

Seventeen *Candida* strains: *Candida albicans* (ATCC 18804, CA 01, CA 05, CA 17), *C. glabrata* (CG RL24m, CG RL34 and CG RL49), *C. krusei* (CK 02, CK 03 and CK Den43), *C. parapsilosis* (CP RL13m, CP RL38 and CP RL52), and *C. tropicalis* (CT 07, CT 72A, CT 72P and ATCC 750) and thirteen dermatophytes strains *Microsporum canis* (MCA 01, MCA 29 and MCA 40), *M. gypseum* (MGY 42, MGY 50 and MGY 58), *Trichophyton mentagrophytes* (TME 16, TME 32, TME 40 and TME 60), and *T. rubrum* (TRU 45, TRU 47 and TRU 51). The CA 01, CG RL24m, CP RL13m, CT 72A, TME 16, TME 60, and TRU 45 are strains resistant to at least one class of antifungals. *Candida* strains were analyzed phenotypically by Vitek Yeast Biochemical Card (BioMerieux Vitek--Hazelwood, Missouri, USA). All strains are from the mycology collection of yeasts of the Federal University of Rio Grande do Sul (Porto Alegre, Brazil). The standard strains (ATCC 18804 and ATCC 750) were obtained from ATCC (American Type Culture Collection, Manassas, VA, USA) and used as control.

Antifungal susceptibility testing {#Sec7}
---------------------------------

Compounds 1--5 were tested against all strains described previously. Thus, the compounds were submitted to the broth microdilution assay to determine their minimum inhibitory concentration (MIC). Each compound was tested at 100 μg ml^−1^, with concentrations ranging from 0.09 to 50 μg ml^−1^ in the assay. Thus, for dermatophytic species and *Candida* spp., the assay was performed according to protocol M38-A2 \[[@CR43]\] and M27-A3 \[[@CR44]\], respectively. Fluconazole (FLC) solution at 64 μg ml^−1^ was used as a drug control for the test.

Cytotoxicity assay {#Sec8}
------------------

Green monkey kidney (Vero®) cells were used for cytotoxicity assay. Vero® cells were added in flasks and cultivated in DMEM High broth (Sigma-Aldrich, St. Louis, Missouri, EUA), supplemented with 20% heat-inactivated fetal bovine serum (FBS - Cripton, Andradina, São Paulo, Brasil), 1% penicillin and streptomycin both at 100 μg/mL (Sigma-Aldrich, St. Louis, Missouri, EUA) in 5% CO~2~ atmosphere, and incubated at 37 °C. When a confluence of 80--90% of the cell monolayer was obtained, the cells were detached to be subjected to the assay. Vero® cells at approximately 7 × 10^3^ cells/well were dispensed into a 96-well microtiter and incubated for 24 h to obtain the cellular monolayer. Then, the cells were treated with compounds 3 and 5 at concentrations ranging from 6.25 to 100 μg ml^−1^ during 48 h at 37 °C in 5% CO~2~ atmosphere. As control without treatment, 0.5% DMSO was used. Then, a solution of MTT 0.5 μg ml^−1^ was added to the cells and the microplates incubated for 2 h at 37 °C. The staining presented by the cells is directly proportional to the number of viable cells and is measured by optical density. The microplates were read in a spectrophotometer (Spectramax 190-Molecular Devices) at 570 nm. The assay was performed in triplicate according to Ishida et al. \[[@CR45]\], with modifications.

Hen's egg test on the chorioallantoic membrane (HET-CAM) {#Sec9}
--------------------------------------------------------

HET-CAM assay has been accepted as an alternative model for in vivo tests because of the high sensitivity of the chorioallantoic membrane to show damages in the presence of irritant compounds. For this study, fresh fertile white Lohmann eggs (Lohmann selected Leghorn, LSL) were selected and maintained under controlled conditions. On the 10th day, the egg shell was removed carefully with a rotary tool (Dremel, WI). Then, 300 μl of compound 5 at 500 μg ml^−1^, positive control 0.1 mol l^−1^ NaOH solution, and negative control 0.9% NaCl solution were added into each egg. The evaluation of effects caused by the compound was observed in 0.5, 2, and 5 min, after its application. The irritation score (IS) was expressed on the following scale: non-irritating or practically non-irritating (0--4.9); moderate irritation (5--8.9), and severe or extreme irritation (9--21) \[[@CR46]\], according to the equation:$$\documentclass[12pt]{minimal}
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Histopathological evaluation in ex vivo model {#Sec10}
---------------------------------------------

The possible dermal toxicity induced by compound 5 was evaluated on pig ear skin samples. Tissue samples from adult male pigs freshly slaughtered by São Clemente (Concordia, SC, Brazil) and supplied to Institute Federal of Santa Catarina (Concordia, SC, Brazil) were used. Pigs were slaughtered according to all rules of the Brazilian Ministry of Agriculture, respecting animal welfare \[[@CR47]\]. Initially, pig ear skin samples were mounted in Franz diffusion cells (Logan Instrument Corp., NJ) with an area of 1.75 cm^2^. The epidermal side of the skin was exposed to phosphate-buffered saline (PBS) pH 7.0 (negative control) and 0.1 mol l^−1^ NaOH solution (positive control), for 6 h each. Under the same conditions, compound 5 was dissolved in PBS buffer at concentrations 25, 100, 200, and 400 μg ml^−1^ and added on the skin samples. Then the treatment and the tissue fragments were collected, fixed in 10% formalin solution with neutral buffer, and stained with hematoxylin and eosin (HE). Finally, the tissues were examined under light microscopy. The experiments were carried out in triplicate.

Micronucleus test {#Sec11}
-----------------

The toxicological study of DNA damage at the chromosomal level is essential to identify the occurrence of chromosomal mutations, an important event in carcinogenesis \[[@CR48]\]. Thus, venous blood was collected from an adult volunteer having over 18 years of non-use of medication by venipuncture. Lymphocytes were obtained by centrifugation gradient and immediately transferred to RPMI 1640 medium (protocol approved by the Ethics Committee of the Federal University of Pampa, under number 27045614.0.0000.5323). Then, cell culture flasks containing compound 5 at 100 μg ml^−1^ were incubated at 37 °C during 72 h along with positive control (bleomycin at 3 μg ml^−1^) and negative control (PBS buffer at pH 7.4). Then, the slides containing the treatments were stained with Renylab® and analyzed under optical microscope at × 1000 magnification. Five hundred cells were counted in each slide and classified for the amount: mononuclear cells with the presence of micronucleus, binuclear cells with micronucleus, cells in necrotic process, and cells in the apoptotic process. The methodology followed Fenech \[[@CR48]\] and Schmid \[[@CR49]\], with modifications.

Acute toxicity test in mealworms {#Sec12}
--------------------------------

For this study, *Tenebrio monitor* larvae (Coleoptera: Tenebrionidae) were supplied by Predadora live food (Porto Alegre, RS, Brazil)*.* The mealworms with a weight between 100 and 200 mg and uniform color, without dark spots or grayish marks, were selected and anesthetized by cooling (2 °C) for 2 minutes. Then, 50 μl of compound 5 at 100 μg ml^−1^ was applied in each larva with support of a microsyringe into the hemocoel, at the second or third visible sternite above the legs, in the ventral portion. The larvae were incubated at 37 °C in Petri dishes containing a rearing diet. The number of dead larvae was recorded at 4 h intervals during 48 h. The assay was performed in triplicate with groups of seven larvae, with a total of twenty-one larvae per each treatment. The methodology followed De Souza et al. \[[@CR50]\], with modifications.

Statistical analysis {#Sec13}
--------------------

All statistical analyses were performed with GraphPad Prism 7.0 (GraphPad Software). The data were analyzed statistically through one-way ANOVA followed by Tukey's test with *p* \< 0.05 value considered significant. The experiment was performed three times in triplicate.

Results and discussion {#Sec14}
======================

Quinoline compounds were obtained from substituted anilines using the adapted methodologies of Skraup and Doebner-von Miller (compound 1), in addition to an innovative methodology that utilized the Heck-Mizoroki reactions (compounds 2--5) (Scheme [1](#Sch1){ref-type="fig"}). How is it possible to observe from the methodology based on Skraup and Doebner-von Miller, the reaction was carried out by reacting the aniline with the α,β-unsaturated ketone, using as the catalyst the bronsted acid to give compound 1 42% yield. In the synthesis based on Heck-Mizoroki, a synthetic innovation was introduced by the protection of 2-iodoaniline with tert-butyl carbamate (BOC), an essential detail in the formation of quinolones. In the first step, the protected aniline was reacted with the α,β-unsaturated ketone in basic conditions and under Palladium catalysis. Then, from the crude reaction, deprotection was performed with the addition of trifluoroacetic acid resulting in yields ranging from great to low (2, 70%; 3, 77%; 4, 37%; and 5, 17%). The variation in yields can be explained mainly by the steric and electronic nature of the different α,β-unsaturated ketones. The compounds were purified by thin layer chromatography and/or by column chromatography. The structures of the synthesized compounds were confirmed by ^1^H NMR, ^13^C NMR, and mass spectral like published previously and shown in [supporting information](#Sec16){ref-type="sec"}.Scheme 1General methodologies used for synthesis of the quinolines and their respective yields

The synthetic versatility presented by the quinoline nucleus facilitates the development of several structurally different derivatives, providing a broad spectrum of biological action \[[@CR51]\]. In this study, positions C-2, C-4, and C-6 of the quinoline nucleus were modified to obtain antifungal active compounds. The quinoline derivatives presented selective antifungal action on the strains tested. Compounds 2 and 3 (MIC ranges 25--50 μg/mL) were active only on yeast, whereas compound 5 (MIC ranges 12.5--25 μg ml^−1^) demonstrated efficacy only on filamentous fungi. This anti-dermatophytic action was more effective, since the compound 5 (geometric means (GM) = 19.14 μg ml^−1^) demonstrated smaller GM values, when compared with the anti-*Candida* action presented by compounds 2 (GM = 50 μg ml^−1^) and 3 (GM = 47.19 μg ml^−1^). In addition to showing the lowest MIC values, compound 5 was active against all dermatophytic strains. On the other hand, compound 4 was active only against a yeast strain, while compound 1 showed no activity on any evaluated fungal species (Table [1](#Tab1){ref-type="table"}).Table 1Minimum inhibitory concentration (MIC μg ml^−1^) values refer to compounds 1--5 against *Candida* spp. and dermatophytes strains*Candida* spp.12345FLCDermatophytes12345FLCATCC 18804\> 505050**\>** 50\> 502MCA 01\> 50\> 50\> 50\> 5012.5\> 64CA 01\> 50\> 50\> 50\> 50**\>** 508MCA 29\> 50\> 50\> 50\> 5012.5\> 64CA 05\> 50\> 5050\> 50\> 5016MCA 40\> 50\> 50\> 50\> 5025\> 64CA 17\> 50\> 5050\> 50\> 508MGY 42\> 50\> 50\>5 0\> 5012.5\> 64CG RL24\> 50\> 5050\> 50\> 5016MGY 50\> 50\> 50\> 50\> 5012.5\> 64CG RL34\> 50\> 5050\> 50\> 5064MGY 58\> 50\> 50\> 50\> 5012.5\> 64CG RL49\> 50\> 50\> 50\> 50\> 5016TME 16\> 50\> 50\> 50\> 5025\> 64CK 02\> 50\> 50\> 50\> 50\> 508TME 32\> 50\> 50\> 50\> 5012.5\> 64CK 03\> 50\> 5050\> 50\> 5064TME 40\> 50\> 50\> 50\> 5012.5\> 64CK Den 43\> 505025\> 50\> 5064TME 60\> 50\> 50\> 50\> 5025\> 64CP RL13\> 50\> 5050\> 50\> 5032TRU 45\> 50\> 50\> 50\> 5025\> 64CP RL38\> 50\> 50\> 50\> 50\> 504TRU 47\> 50\> 50\> 50\> 5025\> 64CP RL52\> 5050\> 50\> 50\> 5032TRU 51\> 50\> 50\> 50\> 5025\> 64CT 07\> 505050\> 50\> 508-\> 50\> 50\> 50\> 50\--CT 72A\> 50\> 5050\> 50\> 50128-\> 50\> 50\> 50\> 50\--CT 72P\> 505050\> 50\> 5064-\> 50\> 50\> 50\> 50\--ATCC 750\> 50\> 5050\> 50\> 504-\> 50-\> 50\> 50\--Geometric mean-5047.19\--17.35Geometric mean\-\-\--19.14-MIC range-50--\> 5050--\> 50\--4--128MIC range\-\-\--12.5--25-*Microsporum canis* (MCA 01, MCA 29, and MCA 40); *Microsporum gypseum* (MGY 42, MGY 50, and MGY 58); *Trichophyton mentagrophytes* (TME 16, TME 32, TME 40, and TME 60); *Trichophyton rubrum* (TRU 45, TRU 47, and TRU 51). *Candida albicans* (CA 01, CA 02, and CA 17); *C. glabrata* (CG RL24, CG RL 34, and CG RL49); *C. krusei* (CK 02, CK 03, and CK Den43); *C. parapsilosis* (CP RL13, CP RL38, and CP RL52); *C. tropicalis* (CT 07, CT 72A, CT 72P, and ATCC 750). Resistant strains at the highest concentration tested for each compound (MIC \> 50 μg ml^−1^) and fluconazole (MIC \> 64 μg ml^−1^). FLC: fluconazole solution used as control of test

The compound 5 has a phenyl substituent at C-4 position of the quinoline ring, suggesting that the presence of this group, directly attached to the nucleus, is fundamental to anti-dermatophytic action when we compare the tested molecules with each other. According to Patel et al. \[[@CR52]\], the introduction of a phenyl substituent into the quinoline ring resulted in a good microbiological action. It is possible to suggest that the introduction of a methyl substituent at C-2 position and a phenyl group at C-4 position of the quinoline ring (compound 5) resulted in higher efficiency when compared with other compounds. The higher efficiency presented by compound 5 may occur due to the inductive effect of the methyl group, facilitating the electronic effects and occurrence of interactions with the biological targets. For El Shehry et al. \[[@CR38]\] and Singh et al. \[[@CR30]\], the introduction of a methyl group into quinoline derivatives showed a good action against *Aspergillus* and *Mycobacterium* genus, respectively. However, only the presence of methyl was not enough for developing action on dermatophytes, since the compounds 1--4 did not present activity on these genera. On the other hand, compounds 2 and 3 present selective anti-*candida* action. These compounds also have a methyl substituent at C-2 position of the quinoline ring. A C-2 methyl and C-4 ethyl disubstitution in the derivative 3 promoted enhances in the yeast activity when compared with a monosubstitution at C-2 position of the quinoline core (2). According to Liberato et al. \[[@CR37]\], derivatives with C-2,4 disubstituents in the quinoline ring presented anti-*Candida* and anti-*Cryptococcus* action. The selective anti-*Candida* action may be due to compounds 2 and 3 have lower molecular weight and lower electrons conjugation when compared with the other compounds. This lower molecular structure could facilitate the penetration of these compounds through yeast cells.

The compounds 1 and 4 were not effective against any genus evaluated. The absence of a substituent at C-2 position along with bromine an electron-withdrawing group at C-6 position of quinoline nucleus could have contributed to the loss of antifungal action by compound 1. Moreover, the ethylphenyl, a flexible electron-rich substituent at C-4 position, has led to the loss of activity by compound 4. This can suggest that the presence of a phenyl group directly linked to the quinoline nucleus can give rigidity necessary for antifungal activity. Finally, we can suggest that the antifungal selectivity presented by quinoline derivatives can be due to its structural alterations since modifications in the substituents attached to the ring interfered in the performance of the biological action of compounds. Thus, the presence of determinate substituents attached to the quinoline nucleus seems to be related for the presence of antifungal potential. However, the number of compounds evaluated is small to certify these structural relationships. The selective action of the compounds on yeasts or filamentous fungi may also be due to the morphological characteristics displayed by these organisms, which may affect the penetration of the compound into fungal cells.

In silico ADME prediction of physical-chemical parameters for quinoline compounds was performed. As a result, all compounds showed satisfactory physicochemical parameters by online platform *Swiss*ADME. All compounds presented LogP compatible with a good oral bioavailability due to lipophilic character, highlight compound 4 with higher LogP (4.29). The prediction of LogS indicated a good oral bioavailability for compounds 4 and 5 (LogS \> − 4). Moreover, all compounds have a percentage of oral absorption (ABS) major to 100 and present acceptable values for probable skin permeation (Table [2](#Tab2){ref-type="table"}). The evaluation of these parameters is fundamental to indicate the potential of a compound as a new drug.Table 2In silico ADME parameters calculated for quinoline derivatives (compounds 1--5)12345MW220.09143.0171.10247.14219.10LogP3.082.453.094.293.84LogS− 3.25−2.51− 3.34− 4.81− 4.20%ABS\> 100\> 100\> 100\> 100\> 100LogKp− 5.31− 5.33− 4.94− 4.39− 4.64*MW*, molecular weight \< 500 g mol^−1^; *LogP*, partition coefficient (\< 5.0); *LogS*, solubility coefficient (\> − 4); *%ABS*, percentage of oral absorption (\> 100); *LogKp*, logarithm of cutaneous permeability; *ADME*, absorption, distribution, metabolism, excretion. The pharmacokinetic parameters were calculated through online platform SwissADME

Due to the higher antifungal efficacy, compounds 3 and 5 were selected for evaluation of cell viability on Vero cells. As a result, the compounds did not show cytotoxicity at concentrations related to their MIC values (12.5--50 μg ml^−1^). Even at the highest concentration evaluated (100 μg ml^−1^), a high percentage of viable cells can be observed in the presence of compounds tested. Thus, there were no significant difference between the groups evaluated when compared with the control (*p* \> 0.05), indicating the absence of cytotoxicity (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Dose-response relationship on the viability of Vero® cells after 48 h of exposition of compounds 3 (**a**) and 5 (**b**) at 6.25, 12.5, 25, 50, and 100 μg ml^−1^. As a cytotoxicity control, 0.5% DMSO was used. Data are expressed as mean ± standard error of three independent experiments

Similar to our findings, diverse studies have shown that quinoline derivatives with microbiological action present low cytotoxicity on Vero cells: IC~50~ \> 30 μg ml^−1^ \[[@CR53]\], IC~50~ \> 200 μg ml^−1^ \[[@CR54]\], and IC~50~ \> 50 μg ml^−1^ \[[@CR55]\]. About the chemical structure, the viability of Vero cells does not seem to depend on the substituents introduced at the C-2.4 positions of the quinoline ring, since two compounds exhibited similar behavior on these cells. The discovery of the compounds with low toxicity is a challenge for antifungal clinical therapy. Most oral antifungal drugs currently used in the medical clinic cause some kind of toxic damage in the patient, such as nephrotoxicity and hepatotoxicy, the main toxic effects related to the literature due to drug \[[@CR18], [@CR20], [@CR21], [@CR56]--[@CR59]\]. However, our results suggest that quinoline derivatives are safe for use in mammalian cells, although in vivo cytotoxicity assays are still required. Because of the greater antifungal efficacy and low cytotoxicity, compound 5 was chosen to proceed with the other toxicity tests in this study.

Like the PBS control, compound 5 was not able to cause chromosomal level DNA damage at concentrations ≤ 100 μg ml^−1^, since both did not induce micronucleus events. Thus, there was no significant difference between compound 5 and PBS control (*p* \> 0.05). However, compound 5 showed a significant difference when compared with bleomycin control (*p* \< 0.05) (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2The mean frequency of micronucleus in binuclear cells expressed as nuclear division index (NDI) after treatment with compound 5 (100 μg ml^−1^), positive control (PC = bleomycin 3 μg ml^−1^), and negative control (NC = phosphate buffer solution**--**PBS). Data expressed as mean ± standard deviation performed at each test triplicate (*n* = 3). The different letters in each group represent a statistically significant difference (*p* \< 0.05)

These data demonstrate the absence of genotoxic potential by compound 5 even at concentrations greater than its MIC's values, suggesting safety for its use in mammalian cells. The importance of developing novel antifungal agents that do not induce genotoxicity is crucial to ensure safety to the patient. According to Uno et al. \[[@CR60]\], quinoline derivatives does not induce the formation of micronucleus events in the bone marrow and gastrointestinal tract cells of rats. Similarly, for Suzuki et al. \[[@CR61]\], structural modifications in a quinoline derivative were unable to induce the formation of micronucleated lung fibroblast cells in the hamster. In opposition to these findings, antifungals used against candidiasis and dermatophytosis can induce severe mutagenicity in the cells of the patient. According to Yuzbasioglu et al. \[[@CR62]\], fluconazole at 25 and 50 μg ml^−1^ increased the micronucleus frequency in human leukocyte cultures. Similarly, griseofulvin, a strong aneuploidy-inducing agent, also promoted the micronucleus events formation in these same cells \[[@CR63]\]. Our results are promising, since quinoline derivatives have a good safety profile when compared to the current antifungals.

At 24 h after administration of compound 5 and PBS control, *T. molitor* larvae survival rate remained at 95% on both treatments. At 48 h, the compound also presented similar behavior on the survival rate of larvae (survival rate of approximately 75%) when compared with PBS control. Moreover, compound 5 was able to maintain a high mealworms survival rate even at concentrations higher than their MIC's values (Fig. [3](#Fig3){ref-type="fig"}). Invertebrate hosts, such as *T. molitor*, have been used as a new alternative model for the evaluation of in vivo systemic toxicity of different compounds, avoiding the use of vertebrates in toxicity preliminary tests \[[@CR50], [@CR64]\]. Our results reinforce the choice of *T. molitor* as a great alternative model for the evaluation of in vivo systemic toxicity. Through the prediction of physical-chemical parameters, compound 5 proved to be lipophilic and presented good coefficients of solubility, leading to a percentage of oral absorption desirable. These results suggest that this compound probably presented a good oral bioavailability in *T. molitor*. This is the first study evaluating the potential of a quinoline derivative to cause systemic toxicity in this organism. However, studies in mammalian animal models are needed to confirm our results.Fig. 3Kaplan--Meier plots showing survival curve of mealworm's submitted to compound 5 at 100 μg ml^−1^ (×) and phosphate buffer solution (PBS) (●)

Assessments of toxicological parameters at the topical level were also performed in compound 5. The antifungal potential coupled with the absence of cytotoxicity and genotoxicity demonstrated by compound 5 led to evaluation of its toxicity in ex vivo alternative models. The compound did not induce irritability and allergenicity on the chorioallantoic membrane of the hen's eggs (IS = 2.47). Thus, the compound was classified as non-irritant. Due to its non-allergenic nature, compound 5 was subject to histopathological evaluation. The compound did not cause changes and histopathological damage on pig ear skin cells at any of concentrations related to their MIC's values (12.5--100 μg ml^−1^), demonstrating possible security for its topical use (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Histopathological evaluation of swine epidermal cells treated with compound 5 and negative control (PSB) at 100 and 400 times magnification. 1A and 2A Swine epidermal cells treated with compound 5 (25 μg ml^−1^) at 100 and 400 times magnification, respectively. 1B and 2B) Swine epidermal cells treated with compound 5 (100 μg ml^−1^) at 100 and 400 times magnification, respectively. 1C and 2C Swine epidermal cells treated with compound 5 (200 μg ml^−1^) at 100 times and 400 times magnification. 1D and 2D Swine epidermal cells treated with compound 5 (400 μg ml^−1^) at 100 and 400 times magnification, respectively. 1E and 2E Swine epidermal cells treated with phosphate buffer solution (PBS) pH 7.0 at 100 and 400 times magnification, respectively

The HET-CAM assay is an important preliminary test for measuring the ability of a compound to induce toxicity to the mucous membranes. Thus, compound 5 did not induce irritability in the chorioallantoic membrane and did not provoke mucosal allergenicity. These previous results are essential and suggest that this compound is safe for topical use. In addition, compound 5 presented Log Kp acceptable for skin permeability, which reinforces its application as a possible antifungal topical therapy. Current antifungals used to treatment of superficial and cutaneous dermatophytosis have present topical toxicity severe. The topical use of terbinafine and ketoconazole cause allergy to the skin and histopathological alternations in the stratum corneum \[[@CR19], [@CR65]\]. Moreover, the topical treatment of dermatophytic onychomycosis with ciclopirox olamine has resulted in nail disorder, pruritus, rash, and contact dermatitis \[[@CR66]\]. In this context, compound 5 is a promising candidate for the development of new topic formulations against superficial and cutaneous dermatophytosis.

Conclusion {#Sec15}
==========

This study is unprecedented and highlights the advantages of knowledge about the pharmacological potential of quinoline derivatives. These compounds have demonstrated selective and potent anti-dermatophytic and anti-yeast action against species of difficult treatment. Compound 5 presents a safe toxicological profile at the topical and systemic level, suggesting its indication as a strong candidate for the development of a new effective compound against dermatophytosis. This study is the starting point for further researches involving the therapeutic applicability of this compound.
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